A diphenylpropylamine is a synthetic compound in which a propylamine chain carries two phenyl groups on the same carbon, a scaffold whose members act as μ-opioid receptor agonists and produce the full spectrum of opioid effects.[1] The class is defined by this shared chemical template rather than by any single receptor profile, but its members converge on opioid pharmacology. It is a narrow, well-bounded sub-class within the broader phenylpropylamine family.
Membership is small and entirely synthetic: the historical analgesic dextropropoxyphene and the long-acting opioid methadone, both arising from mid-twentieth-century programs that sought morphine alternatives. No naturally occurring alkaloids share the scaffold. Despite divergent regulatory fates, both members retain the defining diphenyl chain and act primarily through opioid receptors.
The class produces analgesia, sedation, and the broader opioid effect profile across its dose range. Methadone remains in wide clinical use for chronic pain and for opioid use disorder maintenance, while dextropropoxyphene has been withdrawn from major markets over cardiac safety concerns. At the upper end of exposure, the opioid-mediated suppression of respiratory drive that defines the class becomes the dominant effect.
Pharmacology
Both members converge on μ-opioid receptor (MOR) agonism, the unifying pharmacodynamic of the class and the source of its analgesic, sedative, and respiratory-depressant effects.[2]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| μ-opioid receptor full agonism | methadone | Activates brainstem and limbic opioid circuits to produce analgesia, euphoria, and dose-dependent respiratory suppression |
| μ-opioid receptor weak agonism | dextropropoxyphene | Weaker activation of the same receptors, with analgesic efficacy comparable to acetaminophen alone in many trials[1] |
| NMDA receptor non-competitive antagonism | methadone | Blocks a glutamatergic site implicated in central sensitisation and opioid tolerance, broadening methadone's mechanistic footprint relative to most other opioids[3] |
| Cardiac ion-channel effects | Both members | Methadone prolongs the QT interval; dextropropoxyphene's active metabolite norpropoxyphene blocks cardiac sodium channels in a quinidine-like pattern[4] |
The mechanistic detail varies between members, but the safety endpoint is the same: opioid-mediated suppression of brainstem respiratory drive, additive with any other MOR agonist or CNS depressant on board. Methadone's NMDA antagonism and long, variable half-life shape its clinical profile and its overdose lag, but do not change the underlying opioid liability that both members share.
Substances
The class has two members, both synthetic and both developed in the mid-twentieth century as analgesic alternatives to morphine.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Methadone | — | Full MOR agonist with a long, variable half-life; in wide clinical use for chronic pain and for opioid use disorder maintenance[2] |
| Dextropropoxyphene | — | Weak MOR agonist, withdrawn from major markets in 2010 over cardiotoxicity from its accumulating norpropoxyphene metabolite[1] |
The two members illustrate the class's narrow chemical scope and very different clinical trajectories. They nonetheless share the underlying opioid pharmacology and the cardiac-conduction liability that emerged as a class-level safety signal.
Subjective Effects
Across the class the subjective trajectory tracks deepening μ-opioid receptor activation as exposure rises.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Analgesia, mild sedation, constipation, and nausea, with nausea most common in opioid-naive users |
| Moderate–high | Deepening sedation, euphoria (particularly in opioid-naive individuals), pinpoint pupils, and progressive slowing of breathing |
| High | Unconsciousness, severely depressed or absent breathing, and risk of fatal respiratory failure |
Because analgesia and respiratory depression share a common receptor, the margin between effective dose and dangerous dose narrows as exposure rises. With methadone in particular, peak respiratory depression lags well behind peak analgesia — apparent stability during induction or after a dose increase can mask a still-deepening toxicity.
Safety
Risk profile
The defining acute danger of the diphenylpropylamine class is fatal respiratory depression, mediated by μ-opioid receptor activation at brainstem respiratory centers. The danger is compounded by methadone's long, variable half-life: peak respiratory effect occurs later and persists longer than peak analgesia, so repeat dosing before the prior dose has cleared can produce cumulative, life-threatening suppression.[2]
Both members also carry a class-level cardiac-conduction liability. Methadone prolongs the QT interval and is associated with torsades de pointes; risk rises with dose, with co-administration of other QT-prolonging drugs, with electrolyte abnormalities, and with pre-existing cardiac disease.[4] Dextropropoxyphene produces QRS widening, QT prolongation, and PR-interval changes through its norpropoxyphene metabolite, and this cardiotoxicity at therapeutic exposures was the proximate basis for its global withdrawal.[1]
Combining a diphenylpropylamine with other CNS depressants — benzodiazepines, alcohol, other opioids, or sedating antihistamines — sharply raises the risk of fatal respiratory failure. Methadone's hepatic metabolism through CYP3A4 and CYP2D6 adds further interaction risk: inhibitors of these enzymes can substantially elevate plasma concentrations and precipitate toxicity.[2]
Naloxone, a μ-opioid receptor antagonist, reverses respiratory depression from either member. Because methadone's effects long outlast a single naloxone dose, reversal often requires repeat dosing or a continuous infusion; one ampoule is rarely the end of the intervention.
Tolerance & dependence
Tolerance to the analgesic and euphoric effects of opioids develops with regular use and is a class-wide property; cross-tolerance extends broadly across other μ-opioid receptor agonists.[5] Methadone's NMDA antagonism has been proposed to slow tolerance development relative to pure MOR agonists, though this is a methadone-specific feature rather than a class-level one.[3]
Regular use produces physical dependence characteristic of opioids. Abrupt discontinuation precipitates an abstinence syndrome of autonomic rebound (elevated heart rate, blood pressure, sweating, rhinorrhea, lacrimation), severe musculoskeletal pain, insomnia, gastrointestinal distress, dysphoria, and anxiety. Methadone withdrawal is notable for its delayed onset and protracted duration relative to shorter-acting opioids, and patients commonly continue to experience symptoms well after the last dose.[5]
Opioid withdrawal is generally not immediately life-threatening in otherwise healthy adults, unlike alcohol or benzodiazepine withdrawal. The clinical hazard is different: the severity of withdrawal drives relapse, and relapse after a period of abstinence carries elevated overdose risk because tolerance has fallen.
Recovery
Dependence on diphenylpropylamine opioids is treatable, and the pathway is well-established. A medically supervised gradual taper is the standard route off methadone, with reductions paced to the patient's withdrawal experience.[5]For people with opioid use disorder, the evidence supports continued methadone maintenance over discontinuation: a Cochrane review of randomised trials found maintenance substantially superior to no opioid replacement for retaining patients in treatment and suppressing illicit opioid use.[6] Long-term maintenance is a legitimate treatment outcome. If you or someone you know is dependent on methadone or another opioid, a clinician or an opioid-treatment program can structure a safe taper or a maintenance plan.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2]
- [3]^abSunilkumar, M.M. and Lockman, K. (2018) Practical Pharmacology of Methadone: A Long-acting Opioid — Indian Journal of Palliative Care PMID:29497249
- [4]^abChou, R. and Cruciani, R.A. and Fiellin, D.A. and Compton, P. and Farrar, J.T. and Haigney, M.C. and Inturrisi, C. and Knight, J.R. and Otis-Green, S. and Marcus, S.M. and Mehta, D. and Meyer, M.C. and Portenoy, R. and Savage, S. and Strain, E. and Walsh, S. and Zeltzer, L. (2014) Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society — Journal of Pain doi:10.1016/j.jpain.2014.01.494
- [5]
- [6]^Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. — Cochrane Database of Systematic Reviews doi:10.1002/14651858.cd002209.pub2